

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The company has five novel and differentiated drug development programs. OLINVYK[™] is approved by the FDA. Please see **Important Safety Information** including **Boxed Warning** in the full prescribing information available at OLINVYK.com. The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.

Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting

Sep 21 2020, 7:00 AM EDT

Trevena, Inc. to Present at September Virtual Investor Conferences

Sep 2 2020, 7:00 AM EDT

Trevena Announces Publications of OLINVYK[™] Respiratory Safety Analyses vs. IV Morphine

Aug 26 2020, 7:00 AM EDT

Stock Overview

Symbol	TRVN
Exchange	Nasdaq
Market Cap	434.04m
Last Price	\$2.83
52-Week Range	\$0.46 - \$3.68

09/25/2020 04:00 PM EDT

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
Managing Director
T: 617-430-7576
daniel@lifesciadvisors.com

Management Team

Carrie L. Bourdow

President and Chief Executive Officer

Scott Applebaum

Chief Legal and Compliance Officer, SVP of Regulatory Affairs and Corporate Secretary

Mark A. Demitrack, MD

Senior Vice President, Chief Medical Officer

Barry Shin

Senior Vice President, Chief Financial Officer

Robert T. Yoder

Senior Vice President, Chief Business Officer

Joel S. Solomon, Esq.

Vice President, Legal & Compliance

Linda Wase, MD

Vice President, Clinical Operations and Medical Affairs

Michael S. Kramer

Vice President, Scientific Operations & Alliance Management

Katrine Sutton

Vice President, Finance Planning & Analysis

Michael J. Fossler, Pharm. D., Ph. D., F.C.P.

Vice President, Clinical Development and Quantitative Sciences

Trevena, Inc.

955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.